Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Septerna, Inc.NASDAQ: SEPN

Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026

Income tax expense turns negative

Q3 FY2026 income tax expense was -$4.62M, compared with $0 a year earlier. Trailing-twelve-month income tax expense was -$3.3M.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025, down 46.3 pp from a year earlier.
  • Income tax expense increased in 1 of the last 2 fiscal years.

What to watch

Whether quarterly income tax expense holds near -$4.62M or moves back toward the trailing-twelve-month quarterly average of -$824.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$4.62M-574.9% QoQ
Last fiscal yearDec 2025
$12K+102.4% YoY
LTMSep 2026
-$3.3M-1961.9% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+102.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
12K USD
Year-over-year change
+102.4%
2-year CAGR
-86.8%

Income Tax Expense vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 income tax expense of -$3.3M is the lowest of the 7 companies compared; the peer median is $0.
  • Its year-over-year change of -1961.9% is the lowest of 3, against a peer median of -24.5%.
  • Income tax expense amounts to 3.4% of revenue for SEPN, versus a peer median of 0.0%.
SEPN Competitors Peer median
Income Tax Expense for SEPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$702.57K +51.1%+211.7%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$0 ———
MAZEMaze Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
KLRAKailera Therapeutics, Inc.FY2025$0 ———
VTVTvTv Therapeutics Inc.LTM Mar 2026$0 ——0.0%
BMEABiomea Fusion, Inc.LTM Mar 2026$0 ———
SEPNSepterna, Inc.LTM Sep 2026-$3.3M -1961.9%—3.4%
Peer median (excluding SEPN) $0-24.5%+211.7%0.0%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue151K1.08M45.95M
Cost of Revenue000
Gross Profit151K1.08M45.95M
Gross Margin100.0%100.0%100.0%
Research & Development35.98M65.34M97.58M
Selling, General & Admin9.72M16.56M29.16M
Operating Expenses(1.92M)81.9M126.75M
Depreciation & Amortization848K1.4M1.6M
EBITDA(44.7M)(70.9M)(47.26M)
EBITDA Margin-29604.0%-6594.9%-102.9%
Operating Income2.08M(80.82M)(80.8M)
Operating Margin1374.2%-7518.4%-175.8%
Interest Income2.79M8.62M19.53M
Interest Expense000
Other Income / Expenses2.8M8.53M31.93M
Income Before Tax4.87M(72.3M)(48.87M)
Pre-Tax Margin3225.8%-6725.2%-106.3%
Income Tax Expense691K(498K)12K
Net Income4.18M(71.8M)(48.88M)
Net Margin2768.2%-6678.9%-106.4%
EPS (Basic)0.03(1.93)(1.10)
EPS (Diluted)0.03(1.93)(1.10)
Weighted Avg Shares19.5M37.19M44.26M
Weighted Avg Shares (Diluted)19.5M37.19M44.26M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.